Year |
Citation |
Score |
2022 |
Weilbeer C, Jay D, Donnelly JC, Gentile F, Karimi-Busheri F, Yang X, Mani RS, Yu Y, Elmenoufy AH, Barakat KH, Tuszynski JA, Weinfeld M, West FG. Modulation of ERCC1-XPF Heterodimerization Inhibition Structural Modification of Small Molecule Inhibitor Side-Chains. Frontiers in Oncology. 12: 819172. PMID 35372043 DOI: 10.3389/fonc.2022.819172 |
0.558 |
|
2019 |
Gentile F, Elmenoufy AH, Ciniero G, Jay D, Karimi-Busheri F, Barakat KH, Weinfeld M, West FG, Tuszynski JA. Computer-Aided Drug Design of Small Molecule Inhibitors of the ERCC1-XPF Protein-Protein Interaction. Chemical Biology & Drug Design. PMID 31891209 DOI: 10.1111/Cbdd.13660 |
0.628 |
|
2019 |
Jaballah MY, Serya RAT, Saad N, Khojah SM, Ahmed M, Barakat K, Abouzid KAM. Towards discovery of novel scaffold with potent antiangiogenic activity; design, synthesis of pyridazine based compounds, impact of hinge interaction, and accessibility of their bioactive conformation on VEGFR-2 activities. Journal of Enzyme Inhibition and Medicinal Chemistry. 34: 1573-1589. PMID 31852269 DOI: 10.1080/14756366.2019.1651723 |
0.301 |
|
2019 |
Chen R, Ganesan A, Okoye I, Arutyunova E, Elahi S, Lemieux MJ, Barakat K. Targeting B7-1 in immunotherapy. Medicinal Research Reviews. PMID 31448437 DOI: 10.1002/Med.21632 |
0.302 |
|
2019 |
Elmenoufy A, Gentile F, Jay D, Karimi-Busheri F, Yang X, Soueidan OM, Weilbeer C, Mani RS, Barakat KH, Tuszynski J, Weinfeld M, West FG. Targeting DNA Repair in Tumor Cells via Inhibition of ERCC1-XPF. Journal of Medicinal Chemistry. PMID 31369707 DOI: 10.1021/Acs.Jmedchem.9B00326 |
0.586 |
|
2019 |
Ahmed M, Kumar A, Hobman TC, Barakat K. Structure-based screening and validation of potential dengue virus inhibitors through classical and QM/MM affinity estimation. Journal of Molecular Graphics & Modelling. 90: 128-143. PMID 31082639 DOI: 10.1016/J.Jmgm.2019.04.010 |
0.338 |
|
2018 |
Elsayed NMY, Serya RAT, Tolba MF, Ahmed M, Barakat K, Abou El Ella DA, Abouzid KAM. Design, synthesis, biological evaluation and dynamics simulation of indazole derivatives with antiangiogenic and antiproliferative anticancer activity. Bioorganic Chemistry. 82: 340-359. PMID 30428414 DOI: 10.1016/J.Bioorg.2018.10.071 |
0.333 |
|
2018 |
Groenendyk J, Paskevicius T, Urra H, Viricel C, Wang K, Barakat K, Hetz C, Kurgan L, Agellon LB, Michalak M. Cyclosporine A binding to COX-2 reveals a novel signaling pathway that activates the IRE1α unfolded protein response sensor. Scientific Reports. 8: 16678. PMID 30420769 DOI: 10.1038/S41598-018-34891-W |
0.31 |
|
2018 |
Gentile F, Barakat KH, Tuszynski JA. Computational Characterization of Small Molecules Binding to the Human XPF Active Site and Virtual Screening to Identify Potential New DNA Repair Inhibitors Targeting the ERCC1-XPF Endonuclease. International Journal of Molecular Sciences. 19. PMID 29710850 DOI: 10.3390/Ijms19051328 |
0.63 |
|
2018 |
Feng T, Barakat K. Molecular Dynamics Simulation and Prediction of Druggable Binding Sites. Methods in Molecular Biology (Clifton, N.J.). 1762: 87-103. PMID 29594769 DOI: 10.1007/978-1-4939-7756-7_6 |
0.328 |
|
2018 |
Gentile F, Deriu MA, Barakat K, Danani A, Tuszynski J. A Novel Interaction Between the TLR7 and a Colchicine Derivative Revealed Through a Computational and Experimental Study. Pharmaceuticals (Basel, Switzerland). 11. PMID 29462934 DOI: 10.3390/Ph11010022 |
0.491 |
|
2018 |
Barakat K. Abstract 2503: Rational design of small-molecule immune checkpoints' inhibitors Cancer Research. 78: 2503-2503. DOI: 10.1158/1538-7445.Am2018-2503 |
0.328 |
|
2018 |
Gentile F, Tuszynski JA, Barakat KH. Investigating the Structure of the XPF-ERCC1 Functional Endonuclease using a Computational Approach Biophysical Journal. 114: 45a. DOI: 10.1016/J.Bpj.2017.11.300 |
0.424 |
|
2017 |
Kalyaanamoorthy S, Barakat KH. Binding modes of hERG blockers: an unsolved mystery in the drug design arena. Expert Opinion On Drug Discovery. 1-4. PMID 29240515 DOI: 10.1080/17460441.2018.1418319 |
0.303 |
|
2017 |
Ahmed M, Barakat K. When theory meets experiment: the PD-1 challenge. Journal of Molecular Modeling. 23: 308. PMID 29019005 DOI: 10.1007/S00894-017-3482-X |
0.306 |
|
2017 |
Kalyaanamoorthy S, Barakat KH. Development of Safe Drugs: The hERG Challenge. Medicinal Research Reviews. PMID 28467598 DOI: 10.1002/Med.21445 |
0.357 |
|
2017 |
Sheff JG, Farshidfar F, Bathe OF, Kopciuk K, Gentile F, Tuszynski J, Barakat K, Schriemer DC. Novel allosteric pathway of Eg5 regulation identified through multivariate statistical analysis of HX-MS ligand screening data. Molecular & Cellular Proteomics : McP. PMID 28062800 DOI: 10.1074/Mcp.M116.064246 |
0.518 |
|
2017 |
Ganesan A, Coote ML, Barakat K. Molecular ‘time-machines’ to unravel key biological events for drug design Wiley Interdisciplinary Reviews: Computational Molecular Science. 7. DOI: 10.1002/Wcms.1306 |
0.315 |
|
2016 |
Ahmed M, Pal A, Houghton M, Barakat K. A Comprehensive Computational Analysis for the Binding Modes of Hepatitis C Virus NS5A Inhibitors: The Question of Symmetry. Acs Infectious Diseases. 2: 872-881. PMID 27933783 DOI: 10.1021/Acsinfecdis.6B00113 |
0.379 |
|
2016 |
Ganesan A, Coote ML, Barakat K. Molecular dynamics-driven drug discovery: Leaping forward with confidence. Drug Discovery Today. PMID 27890821 DOI: 10.1016/J.Drudis.2016.11.001 |
0.334 |
|
2016 |
Gentile F, Tuszynski JA, Barakat KH. Modelling DNA Repair Pathways: Recent Advances and Future Directions. Current Pharmaceutical Design. PMID 27093954 DOI: 10.2174/1381612822666160420141435 |
0.617 |
|
2016 |
Gentile F, Tuszynski JA, Barakat KH. New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy. Journal of Molecular Graphics & Modelling. 65: 71-82. PMID 26939044 DOI: 10.1016/J.Jmgm.2016.02.010 |
0.641 |
|
2015 |
El-Labbad EM, Ismail MA, Abou El Ella DA, Ahmed M, Wang F, Barakat K, Abouzid KA. Discovery of novel peptidomimetics as irreversible CHIKV nsP2 protease inhibitors using quantum mechanical based ligand descriptors". Chemical Biology & Drug Design. PMID 26212366 DOI: 10.1111/Cbdd.12621 |
0.341 |
|
2015 |
Ahmed M, Wang F, Levin A, Le C, Eltayebi Y, Houghton M, Tyrrell L, Barakat K. Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA. Drug Discovery Today. 20: 548-61. PMID 25622780 DOI: 10.1016/J.Drudis.2015.01.008 |
0.303 |
|
2015 |
Barakat KH, Anwar-Mohamed A, Tuszynski JA, Robins MJ, Tyrrell DL, Houghton M. A Refined Model of the HCV NS5A protein bound to daclatasvir explains drug-resistant mutations and activity against divergent genotypes. Journal of Chemical Information and Modeling. 55: 362-73. PMID 24730573 DOI: 10.1021/Ci400631N |
0.496 |
|
2015 |
Barakat K. Immune Checkpoints Inhibitors: A Single Antiviral and Anticancer Magic Bullet Journal of Pharmaceutical Care & Health Systems. 2: 1-2. DOI: 10.4172/2376-0419.1000E127 |
0.325 |
|
2015 |
Ahmed M, Barakat K. Baby Steps Toward Modelling The Full human Programmed Death-1 (PD-1) Pathway Receptors and Clinical Investigation. 2. DOI: 10.14800/Rci.825 |
0.381 |
|
2014 |
Hu G, Wang K, Groenendyk J, Barakat K, Mizianty MJ, Ruan J, Michalak M, Kurgan L. Human structural proteome-wide characterization of Cyclosporine A targets. Bioinformatics (Oxford, England). 30: 3561-6. PMID 25172926 DOI: 10.1093/Bioinformatics/Btu581 |
0.353 |
|
2014 |
Anwar-Mohamed A, Barakat KH, Bhat R, Noskov SY, Tyrrell DL, Tuszynski JA, Houghton M. A human ether-á-go-go-related (hERG) ion channel atomistic model generated by long supercomputer molecular dynamics simulations and its use in predicting drug cardiotoxicity. Toxicology Letters. 230: 382-92. PMID 25127758 DOI: 10.1016/J.Toxlet.2014.08.007 |
0.502 |
|
2014 |
Barakat K. Do We Need Small Molecule Inhibitors for the Immune Checkpoints Journal of Pharmaceutical Care & Health Systems. 1: 1-2. DOI: 10.4172/2376-0419.1000E119 |
0.311 |
|
2014 |
Barakat KH, Houghton M, Tyrrel DL, Tuszynski JA. Rational Drug Design International Journal of Computational Models and Algorithms in Medicine. 4: 59-85. DOI: 10.4018/Ijcmam.2014010104 |
0.51 |
|
2013 |
Barakat KH, Law J, Prunotto A, Magee WC, Evans DH, Tyrrell DL, Tuszynski J, Houghton M. Detailed computational study of the active site of the hepatitis C viral RNA polymerase to aid novel drug design. Journal of Chemical Information and Modeling. 53: 3031-43. PMID 24116674 DOI: 10.1021/Ci4003969 |
0.517 |
|
2013 |
Barakat KH, Huzil JT, Jordan KE, Evangelinos C, Houghton M, Tuszynski J. A computational model for overcoming drug resistance using selective dual-inhibitors for aurora kinase A and its T217D variant. Molecular Pharmaceutics. 10: 4572-89. PMID 24094068 DOI: 10.1021/Mp4003893 |
0.529 |
|
2013 |
Jordheim LP, Barakat KH, Heinrich-Balard L, Matera EL, Cros-Perrial E, Bouledrak K, El Sabeh R, Perez-Pineiro R, Wishart DS, Cohen R, Tuszynski J, Dumontet C. Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells. Molecular Pharmacology. 84: 12-24. PMID 23580445 DOI: 10.1124/Mol.112.082347 |
0.591 |
|
2012 |
Barakat KH, Jordheim LP, Perez-Pineiro R, Wishart D, Dumontet C, Tuszynski JA. Virtual screening and biological evaluation of inhibitors targeting the XPA-ERCC1 interaction. Plos One. 7: e51329. PMID 23272099 DOI: 10.1371/Journal.Pone.0051329 |
0.564 |
|
2012 |
Tuszynski JA, Craddock TJ, Mane JY, Barakat K, Tseng CY, Gajewski M, Winter P, Alisaraie L, Patterson J, Carpenter E, Wang W, Deyholos MK, Li L, Sun X, Zhang Y, et al. Modeling the yew tree tubulin and a comparison of its interaction with paclitaxel to human tubulin. Pharmaceutical Research. 29: 3007-21. PMID 22833053 DOI: 10.1007/S11095-012-0829-Y |
0.71 |
|
2012 |
Barakat K, Gajewski M, Tuszynski JA. DNA repair inhibitors: the next major step to improve cancer therapy. Current Topics in Medicinal Chemistry. 12: 1376-90. PMID 22794314 DOI: 10.2174/156802612801319070 |
0.764 |
|
2012 |
Craddock TJ, St George M, Freedman H, Barakat KH, Damaraju S, Hameroff S, Tuszynski JA. Computational predictions of volatile anesthetic interactions with the microtubule cytoskeleton: implications for side effects of general anesthesia. Plos One. 7: e37251. PMID 22761654 DOI: 10.1371/Journal.Pone.0037251 |
0.462 |
|
2012 |
Barakat K, Gajewski M, Tuszynski J. DNA Repair Inhibitors: Our Last Disposal to Improve Cancer Therapy. Current Topics in Medicinal Chemistry. PMID 22690684 |
0.767 |
|
2012 |
Barakat KH, Gajewski MM, Tuszynski JA. DNA polymerase beta (pol β) inhibitors: a comprehensive overview. Drug Discovery Today. 17: 913-20. PMID 22561893 DOI: 10.1016/J.Drudis.2012.04.008 |
0.75 |
|
2012 |
Friesen DE, Barakat KH, Semenchenko V, Perez-Pineiro R, Fenske BW, Mane J, Wishart DS, Tuszynski JA. Discovery of small molecule inhibitors that interact with γ-tubulin. Chemical Biology & Drug Design. 79: 639-52. PMID 22268380 DOI: 10.1111/J.1747-0285.2012.01340.X |
0.547 |
|
2011 |
Barakat K, Issack BB, Stepanova M, Tuszynski J. Effects of temperature on the p53-DNA binding interactions and their dynamical behavior: comparing the wild type to the R248Q mutant. Plos One. 6: e27651. PMID 22110706 DOI: 10.1371/Journal.Pone.0027651 |
0.527 |
|
2011 |
Barakat KH, Mane JY, Tuszynski JA. Virtual screening: An overview on methods and applications Handbook of Research On Computational and Systems Biology: Interdisciplinary Applications. 28-60. DOI: 10.4018/978-1-60960-491-2.ch002 |
0.425 |
|
2010 |
Barakat K, Tuszynski J. Relaxed complex scheme suggests novel inhibitors for the lyase activity of DNA polymerase beta. Journal of Molecular Graphics & Modelling. 29: 702-16. PMID 21194999 DOI: 10.1016/J.Jmgm.2010.12.003 |
0.591 |
|
2010 |
Bennett MJ, Barakat K, Huzil JT, Tuszynski J, Schriemer DC. Discovery and characterization of the laulimalide-microtubule binding mode by mass shift perturbation mapping. Chemistry & Biology. 17: 725-34. PMID 20659685 DOI: 10.1016/J.Chembiol.2010.05.019 |
0.458 |
|
2010 |
Barakat K, Mane J, Friesen D, Tuszynski J. Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions Journal of Molecular Graphics and Modelling. 28: 555-568. PMID 20056466 DOI: 10.1016/J.Jmgm.2009.12.003 |
0.499 |
|
2009 |
Huzil JT, Barakat K, Tuszynski JA. Electrostatic contributions to colchicine binding within tubulin isotypes. Electromagnetic Biology and Medicine. 28: 355-64. PMID 20017626 DOI: 10.3109/15368370903206606 |
0.509 |
|
2009 |
Barakat KH, Torin Huzil J, Luchko T, Jordheim L, Dumontet C, Tuszynski J. Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening approach. Journal of Molecular Graphics & Modelling. 28: 113-30. PMID 19473860 DOI: 10.1016/J.Jmgm.2009.04.009 |
0.598 |
|
Show low-probability matches. |